Cognition Therapeutics, Inc.

https://cogrx.com

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small-molecule therapeutics. The company focuses on addressing age-related neurodegenerative diseases and disorders of the central nervous system (CNS) and retina. Its core mission is to develop disease-modifying treatments for patients suffering from these debilitating conditions, many of which currently have limited or no approved therapies. The company's headquarters are located in Purchase, New York.

The company's lead product candidate is zervimesine (also known as CT1812), an orally administered small molecule. Zervimesine is designed to protect neuronal synapses by preventing the binding of toxic oligomers of pathogenic proteins, such as beta-amyloid and alpha-synuclein, which are implicated in neurodegenerative disorders like Alzheimer's disease and dementia with Lewy bodies (DLB). Cognition Therapeutics leverages its proprietary NICE (Novel Improved Conditioned Extraction) screening platform to advance its pipeline beyond Alzheimer's disease into related indications.

Cognition Therapeutics became a publicly traded company on October 8, 2021, with its initial public offering (IPO) priced at $12.00 on the Nasdaq Global Market. Lisa Ricciardi serves as the Chief Executive Officer, a position she assumed in March 2020. Recent developments include the completion of enrollment for the Phase 2 START study in early Alzheimer's disease in November 2025. The company is also progressing zervimesine toward a registrational program for Dementia with Lewy Bodies psychosis, following positive Phase 2 SHIMMER data and discussions with the FDA in early 2026. The company's research and development efforts are significantly supported by non-dilutive funding, having secured approximately $171 million in cumulative grants, primarily from the National Institute on Aging (NIA).

Latest updates

Cognition Therapeutics to Detail Alzheimer's, DLB Pipeline at Needham Conference

Event summary

  • Cognition Therapeutics’ CEO, Lisa Ricciardi, will present at the Needham Virtual Healthcare Conference on April 13th.
  • The presentation will focus on updates to the company’s development programs for Alzheimer's disease and dementia with Lewy bodies (DLB).
  • Zervimesine (CT1812) is the company's lead candidate, currently in Phase 2 trials for Alzheimer’s and DLB.
  • Cognition Therapeutics has received nearly $200 million in NIH and foundation grants.

The big picture

Cognition Therapeutics is operating in a crowded neurodegenerative disease space, where clinical trial failures are common and regulatory hurdles are high. The company's focus on DLB psychosis, a relatively underserved area within dementia, presents a potential niche, but also carries the risk of limited market size. The success of zervimesine hinges on demonstrating consistent efficacy and safety across multiple trials, and securing sufficient funding to support a potentially lengthy development process.

What we're watching

Clinical Efficacy
The conference presentation will be scrutinized for any data suggesting whether initial efficacy signals observed in earlier trials, particularly the SHIMMER study for DLB, will translate to later-stage trials and ultimately regulatory approval.
Funding Runway
Given the substantial grant funding already secured, the company's ability to secure additional capital, particularly if late-stage trials are initiated, will be a key determinant of long-term viability.
Regulatory Pathway
The USAN adoption of zervimesine is a procedural step, but the FDA's appetite for novel therapies targeting DLB psychosis, a significant unmet need, will shape the company’s regulatory strategy and timelines.

Cognition Therapeutics Advances DLB Treatment, Eyes FDA Meeting

Event summary

  • Cognition Therapeutics is advancing zervimesine (CT1812) for the treatment of dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER trial results.
  • The company expects to meet with the FDA's Division of Psychiatry in Q2 2026 to discuss a registrational plan for DLB psychosis.
  • A Phase 2 START study in 545 patients with MCI and early Alzheimer's disease is fully enrolled and data readout is expected in 2H 2027, funded by an NIH grant.
  • Zervimesine demonstrated a 95% reduction in cognitive decline in patients with low p-tau217 levels in a Phase 2 Alzheimer's study.

The big picture

Cognition's focus on DLB psychosis represents a strategic shift towards a smaller, underserved market with potentially less competition than the broader Alzheimer's space. The reliance on NIH grants underscores the company's funding challenges and dependence on external sources. The observed efficacy in patients with lower p-tau217 levels suggests a biomarker-driven approach to Alzheimer's treatment, a growing trend in the field.

What we're watching

Regulatory Risk
The upcoming FDA meeting will be critical; a less-than-positive outcome could significantly impact the DLB psychosis development timeline and valuation.
Clinical Efficacy
The success of the START trial, particularly in patients with low p-tau217 levels, will determine the viability of zervimesine as an Alzheimer's treatment.
Concomitant Use
Data on the use of zervimesine alongside existing therapies like Kisunla and Leqembi will be informative regarding market adoption and potential combination strategies.

Cognition Therapeutics Narrows Focus to DLB Psychosis, Burns Cash

Event summary

  • Cognition Therapeutics reported $37.0 million in cash and $35.7 million in remaining grant funds as of December 31, 2025, projecting sufficient runway through Q2 2027.
  • The company is prioritizing zervimesine (CT1812) for the treatment of dementia with Lewy bodies (DLB) psychosis, following feedback from regulators.
  • Enrollment is complete for the Phase 2 ‘START’ trial in early Alzheimer’s disease, with topline results expected in 2027.
  • R&D expenses decreased to $37.2 million in 2025 from $41.7 million in 2024, driven by completed clinical trials.

The big picture

Cognition's strategic pivot towards DLB psychosis reflects the limited treatment options and unmet need in this patient population, but also concentrates risk on a single indication. The company's reliance on grant funding and its relatively short cash runway highlight the financial pressures inherent in early-stage drug development, particularly in neurodegenerative diseases where clinical trials are lengthy and expensive. The decision to deprioritize Alzheimer's, a much larger market, suggests a calculated gamble based on regulatory feedback and the potential for faster approval pathways for DLB psychosis.

What we're watching

Regulatory Risk
The upcoming FDA meeting regarding the DLB psychosis program will be critical; a negative outcome could significantly impact the company's valuation and development timeline.
Clinical Execution
The delayed topline results from the START trial in Alzheimer’s disease will dictate the future direction of zervimesine development, potentially leading to a shift in focus or abandonment of the program.
Financial Sustainability
The company's cash runway, while currently projected to extend through Q2 2027, will be heavily influenced by clinical trial costs and the success of securing additional grant funding.

Cognition Therapeutics to Detail 2025 Results, Zervimesine Progress

Event summary

  • Cognition Therapeutics will release Q4 and full-year 2025 financial results on March 26, 2026, prior to market open.
  • A conference call is scheduled for 8:30 a.m. ET on March 26, 2026, to discuss the results and provide a business update.
  • The company’s lead candidate, zervimesine (CT1812), is in Phase 2 trials for DLB and Alzheimer’s disease.
  • Cognition Therapeutics has received approximately $200 million in NIH and related foundation grants.

The big picture

Cognition Therapeutics operates in a high-risk, high-reward sector focused on neurodegenerative diseases, a market with significant unmet need and increasing investment. The company's progress hinges on the success of zervimesine, a drug targeting toxic oligomers, and its ability to secure further funding and navigate the complex regulatory landscape. The $200 million in prior grants underscores the strategic importance of this research area, but also highlights the financial vulnerability of companies reliant on non-dilutive funding.

What we're watching

Clinical Efficacy
The reported results from Phase 2 trials of zervimesine will be critical to assess the drug's potential for advancement, particularly given the competitive landscape in Alzheimer's and DLB therapies.
Grant Dependency
The company's reliance on substantial NIH and foundation grants necessitates monitoring the success rate of future funding applications and their impact on the company’s burn rate.
Regulatory Pathway
The clarity and speed of a potential regulatory pathway for zervimesine will be heavily influenced by the outcome of ongoing clinical trials and interactions with regulatory agencies.

Cognition Data Suggests Zervimesine May Offer DLB Psychosis Treatment Option

Event summary

  • Cognition Therapeutics presented Phase 2 (COG1201 SHIMMER) data at AD/PD 2026 showing zervimesine slowed decline on the Neuropsychiatric Index (NPI-12) by 86% versus placebo in patients with Dementia with Lewy Bodies (DLB).
  • The data suggests zervimesine may address neuropsychiatric symptoms, a significant unmet need in DLB, potentially offering a tolerable alternative to traditional antipsychotics.
  • Following a Type C meeting with the FDA, Cognition plans to advance zervimesine into a late-stage clinical trial for DLB psychosis.
  • The SHIMMER study (NCT05225415) involved patients with mild-to-moderate DLB.

The big picture

DLB is a debilitating neurodegenerative disorder with a high prevalence of neuropsychiatric symptoms, often poorly managed by existing treatments due to adverse effects. Cognition’s data suggests zervimesine could fill a critical gap by offering a disease-modifying approach to psychosis in DLB, potentially reducing caregiver burden and healthcare costs. The company’s decision to pursue a late-stage trial is a significant commitment, reflecting the potential market opportunity and the unmet medical need.

What we're watching

Clinical Efficacy
The success of the planned late-stage trial for DLB psychosis will be crucial in validating the Phase 2 findings and establishing zervimesine's clinical utility.
Regulatory Pathway
The FDA’s acceptance of Cognition’s Type C meeting suggests a potential pathway for approval, but the agency’s requirements for demonstrating safety and efficacy in a larger trial remain to be seen.
Market Adoption
Given the limited treatment options and significant unmet need for DLB psychosis, the speed with which physicians adopt zervimesine, if approved, will depend on its demonstrated safety profile and perceived efficacy relative to existing alternatives.

Cognition Therapeutics Prioritizes DLB Psychosis Path for Zervimesine

Event summary

  • Cognition Therapeutics plans to pursue a registrational path for zervimesine (CT1812) to treat dementia with Lewy bodies (DLB) psychosis, following a Type C meeting with the FDA in January 2026.
  • The Phase 2 ‘SHIMMER’ study demonstrated an 86% slowing of decline on the NPI-12 scale for zervimesine versus placebo in DLB patients.
  • The next clinical study will focus on neuropsychiatric and behavioral symptoms, with randomization to 100mg zervimesine or placebo daily.
  • DLB psychosis affects approximately 75% of DLB patients, a population with limited treatment options due to intolerance of traditional antipsychotics.
  • The NIH has provided approximately $30 million in grant funding (R01AG071643) to support the SHIMMER study.

The big picture

Cognition’s decision to prioritize DLB psychosis represents a strategic shift towards a niche market with significant unmet need, given the lack of approved therapies and the challenges associated with treating this patient population. This focus carries inherent risks, as regulatory pathways for rare disease treatments can be unpredictable, but also offers the potential for accelerated approval and market exclusivity if clinical trials are successful. The company’s reliance on NIH grant funding also introduces a dependency that investors should monitor.

What we're watching

Regulatory Risk
The FDA’s willingness to accept the Phase 2 data as sufficient for registration remains uncertain, and Cognition’s mid-year meeting will be critical in shaping the program’s design and timeline.
Clinical Efficacy
The observed benefit in the SHIMMER study must be replicated in a larger, pivotal trial to support regulatory approval and demonstrate a clinically meaningful impact on patient outcomes.
Market Adoption
Given the patient population's sensitivity to traditional antipsychotics, the successful launch of zervimesine will depend on demonstrating a superior safety profile and establishing clear guidelines for its use.

Cognition Extends DLB Trial Access, Signals FDA Endpoint Discussion

Event summary

  • Cognition Therapeutics is extending its expanded access program (EAP) for Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB), allowing participants additional treatment months beyond the initial 12-month plan.
  • The EAP, initiated in June 2025, currently involves 32 participants across eight clinical sites.
  • Cognition held a Type C meeting with the FDA on January 21, 2026, to discuss clinically meaningful endpoints for future DLB studies.
  • The company has implemented a strategy to reduce patient travel burden by enabling local physicians to conduct routine monitoring.

The big picture

Cognition's extension of the EAP and ongoing discussions with the FDA highlight the challenges in developing therapies for DLB, a complex and underserved neurological condition. The company's focus on patient-centric operational strategies, like decentralized monitoring, reflects a broader trend in clinical trials aimed at improving patient access and retention. The Type C meeting outcome will be a critical inflection point for the Zervimesine program and its potential to address a significant unmet medical need.

What we're watching

Regulatory Risk
The FDA’s feedback on clinically meaningful endpoints, expected in February, will be crucial in shaping the design of future DLB trials and could impact Zervimesine’s development pathway.
Efficacy Signals
The favorable feedback from EAP participants, while encouraging, needs to be rigorously assessed for genuine efficacy signals and not solely attributed to placebo or supportive care.
Operational Scalability
The success of the decentralized monitoring model implemented in the EAP will be a key factor in determining the feasibility of broader clinical trial implementation and patient recruitment.

Cognition Therapeutics Gains FDA Input on DLB Study Design

Event summary

  • Cognition Therapeutics held a Type C meeting with the FDA on January 21, 2026, to discuss the Phase 2b study design for Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB).
  • The meeting focused on identifying clinically meaningful endpoints for the upcoming Phase 2b trial.
  • Cognition anticipates receiving the formal meeting minutes later in Q1 2026.
  • Zervimesine (CT1812) is an oral medication targeting Aβ and α-synuclein, proteins implicated in both Alzheimer's and DLB.

The big picture

Cognition's progress on Zervimesine represents a rare opportunity in the DLB space, a disease area with significant unmet need and a limited treatment landscape. The Type C meeting is a crucial step in navigating the FDA approval pathway, but the ultimate success depends on demonstrating efficacy and securing ongoing financial support. The broader neurodegenerative disease market is attracting substantial investment, but clinical trial failures remain a significant risk.

What we're watching

Regulatory Risk
The content of the forthcoming FDA meeting minutes will be critical; any significant pushback on endpoints could necessitate a costly and time-consuming study redesign.
Clinical Efficacy
Given the lack of approved therapies for DLB, the Phase 2b trial’s success hinges on demonstrating meaningful clinical benefit, which may be challenging to achieve with current endpoints.
Funding Stability
The company's reliance on $81 million in NIA grant support highlights a potential vulnerability; continued funding will be essential to advance the program.
CID: 559